Met Life Investment Management, LLC Recursion Pharmaceuticals, Inc. Transaction History

Met Life Investment Management, LLC

$14.7 Billion
Q1 2024

A detailed history of Met Life Investment Management, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 72,161 shares of RXRX stock, worth $516,672. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,161

Holding current value

$516,672

% of portfolio

0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.13 - $15.52 $658,829 - $1.12 Million	72,161 New	72,161 $719,000
Q2 2023 Apr 29, 2024	BUY	$4.56 - $9.94 $329,054 - $717,280	72,161 New	72,161 $539,000
Q1 2023 May 09, 2024	BUY	$6.42 - $9.64 $463,273 - $695,632	72,161 New	72,161 $481 Million
Q2 2022 May 10, 2024	BUY	$5.04 - $9.26 $40,955 - $75,246	8,126 Added 12.69%	72,161 $587,000
Q2 2022 Mar 22, 2023	BUY	$5.04 - $9.26 $40,955 - $75,246	8,126 Added 12.69%	72,161 $587,000

Q2 2022 Aug 11, 2022	BUY	$5.04 - $9.26 $40,955 - $75,246	8,126 Added 12.69%	72,161 $587,000
Q1 2022 May 10, 2024	BUY	$6.16 - $18.03 $394,455 - $1.15 Million	64,035 New	64,035 $458,000
Q1 2022 Jun 20, 2023	SELL	$6.16 - $18.03 $50,056 - $146,511	-8,126 Reduced 11.26%	64,035 $458,000
Q1 2022 Mar 22, 2023	BUY	$6.16 - $18.03 $140,651 - $411,678	22,833 Added 55.42%	64,035 $458,000
Q1 2022 May 12, 2022	BUY	$6.16 - $18.03 $140,651 - $411,678	22,833 Added 55.42%	64,035 $458,000
Q4 2021 May 17, 2024	BUY	$16.14 - $21.86 $491,479 - $665,658	30,451 Added 283.24%	41,202 $705,000
Q4 2021 Jun 21, 2023	SELL	$16.14 - $21.86 $499,678 - $676,763	-30,959 Reduced 42.9%	41,202 $705,000
Q4 2021 Mar 22, 2023	BUY	$16.14 - $21.86 $491,479 - $665,658	30,451 Added 283.24%	41,202 $705,000
Q4 2021 Feb 15, 2022	BUY	$16.14 - $21.86 $491,479 - $665,658	30,451 Added 283.24%	41,202 $706,000
Q3 2021 May 17, 2024	BUY	$19.03 - $41.33 $38,878 - $84,437	2,043 Added 23.46%	10,751 $247,000
Q3 2021 Jun 21, 2023	SELL	$19.03 - $41.33 $1.17 Million - $2.54 Million	-61,410 Reduced 85.1%	10,751 $247,000
Q3 2021 Mar 22, 2023	BUY	$19.03 - $41.33 $38,878 - $84,437	2,043 Added 23.46%	10,751 $247,000
Q3 2021 Nov 15, 2021	BUY	$19.03 - $41.33 $38,878 - $84,437	2,043 Added 23.46%	10,751 $247,000
Q2 2021 May 17, 2024	SELL	$18.0 - $37.42 $1.14 Million - $2.37 Million	-63,453 Reduced 87.93%	8,708 $317,000
Q2 2021 Jun 21, 2023	SELL	$18.0 - $37.42 $1.14 Million - $2.37 Million	-63,453 Reduced 87.93%	8,708 $317,000
Q2 2021 Mar 22, 2023	SELL	$18.0 - $37.42 $1.14 Million - $2.37 Million	-63,453 Reduced 87.93%	8,708 $317,000
Q2 2021 Aug 16, 2021	BUY	$18.0 - $37.42 $156,744 - $325,853	8,708 New	8,708 $318,000

Others Institutions Holding RXRX

# of Institutions

260

Shares Held

192M

Call Options Held

787K

Put Options Held

1.52M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.29B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account

Met Life Investment Management, LLC Recursion Pharmaceuticals, Inc. Transaction History